Lambin Philippe, Zindler Jaap, Vanneste Ben, van de Voorde Lien, Jacobs Maria, Eekers Daniëlle, Peerlings Jurgen, Reymen Bart, Larue Ruben T H M, Deist Timo M, de Jong Evelyn E C, Even Aniek J G, Berlanga Adriana J, Roelofs Erik, Cheng Qing, Carvalho Sara, Leijenaar Ralph T H, Zegers Catharina M L, van Limbergen Evert, Berbee Maaike, van Elmpt Wouter, Oberije Cary, Houben Ruud, Dekker Andre, Boersma Liesbeth, Verhaegen Frank, Bosmans Geert, Hoebers Frank, Smits Kim, Walsh Sean
a Department of Radiation Oncology (MAASTRO) , GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre , Maastricht , The Netherlands.
Acta Oncol. 2015;54(9):1289-300. doi: 10.3109/0284186X.2015.1062136. Epub 2015 Sep 23.
Trials are vital in informing routine clinical care; however, current designs have major deficiencies. An overview of the various challenges that face modern clinical research and the methods that can be exploited to solve these challenges, in the context of personalised cancer treatment in the 21st century is provided.
The purpose of this manuscript, without intending to be comprehensive, is to spark thought whilst presenting and discussing two important and complementary alternatives to traditional evidence-based medicine, specifically rapid learning health care and cohort multiple randomised controlled trial design. Rapid learning health care is an approach that proposes to extract and apply knowledge from routine clinical care data rather than exclusively depending on clinical trial evidence, (please watch the animation: http://youtu.be/ZDJFOxpwqEA). The cohort multiple randomised controlled trial design is a pragmatic method which has been proposed to help overcome the weaknesses of conventional randomised trials, taking advantage of the standardised follow-up approaches more and more used in routine patient care. This approach is particularly useful when the new intervention is a priori attractive for the patient (i.e. proton therapy, patient decision aids or expensive medications), when the outcomes are easily collected, and when there is no need of a placebo arm.
Truly personalised cancer treatment is the goal in modern radiotherapy. However, personalised cancer treatment is also an immense challenge. The vast variety of both cancer patients and treatment options makes it extremely difficult to determine which decisions are optimal for the individual patient. Nevertheless, rapid learning health care and cohort multiple randomised controlled trial design are two approaches (among others) that can help meet this challenge.
试验对于指导常规临床护理至关重要;然而,当前的设计存在重大缺陷。本文概述了21世纪个性化癌症治疗背景下现代临床研究面临的各种挑战以及可用于解决这些挑战的方法。
本手稿并非旨在全面阐述,而是在介绍和讨论传统循证医学的两种重要且互补的替代方法时引发思考,具体为快速学习医疗保健和队列多重随机对照试验设计。快速学习医疗保健是一种提议从常规临床护理数据中提取和应用知识,而非仅仅依赖临床试验证据的方法(请观看动画:http://youtu.be/ZDJFOxpwqEA)。队列多重随机对照试验设计是一种实用方法,旨在利用越来越多地用于常规患者护理的标准化随访方法来帮助克服传统随机试验的弱点。当新干预措施对患者具有先验吸引力(即质子治疗、患者决策辅助工具或昂贵药物)、结局易于收集且无需安慰剂组时,这种方法特别有用。
真正的个性化癌症治疗是现代放射治疗的目标。然而,个性化癌症治疗也是一项巨大的挑战。癌症患者和治疗选择的种类繁多,使得确定哪些决策对个体患者最为合适极为困难。尽管如此,快速学习医疗保健和队列多重随机对照试验设计是(众多方法中)有助于应对这一挑战的两种方法。